top of page

80 + studies prove natural immunity is better and safer than the vaccines

Need for COVID-19 vaccine in previously infected individuals

SARS-CoV-2-specific T-cell immunity in COVID-19 and SARS cases and uninfected controls

Comparison of natural SARS-CoV-2 immunity with vaccine-induced immunity: reinfections versus breakthrough infections

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

Large-scale study of antibody titer decline after BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Risk of SARS-CoV-2 reinfection in Austria

SARS-CoV-2 specific T cells induced by mRNA vaccine recognize B.1.1.7 and B.1.351 variants but differ in longevity and homing properties depending on previous infection status

Good news: mild COVID-19 induces long-lasting antibody protection

Robust neutralizing antibodies against SARS-CoV-2 infection persist for months

Evolution of antibody immunity to SARS-CoV-2

Persistence of neutralizing antibodies one year after SARS-CoV-2 infection in humans

Quantification of the risk of reinfection by SARS – CoV – 2 over time

Natural immunity to covid is powerful. Legislators seem afraid to say so

SARS-CoV-2 elicits strong adaptive immune responses regardless of disease severity

protection from prior SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: a three-month national experience from Israel

Incidence of SARS-CoV-2 infection among previously infected or vaccinated employees

Having SARS-CoV-2 once confers much greater immunity than a vaccine, but vaccination remains vital

Humoral and cellular immunities sustained during one year of COVID-19 convalescents

SARS-CoV-2-specific functional immune memory persists after mild COVID-19

Discrete immune response signature to SARS-CoV-2 mRNA vaccination against infection

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

SARS-CoV-2 infection rates of antibody-positive healthcare workers compared with antibody-negative healthcare workers in England: a large multicenter prospective cohort study (SIREN)

Peak pandemic SARS-CoV-2 infection and seroconversion rates in frontline healthcare workers in London

Antibodies to SARS-CoV-2 are associated with protection against reinfection

longitudinal analysis shows extensive and long-lasting immune memory after SARS-CoV-2 infection with persistent antibody responses and memory B and T cells

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

Detection of SARS-CoV-2-specific humoral and cellular immunity in convalescent individuals by COVID-19

Robust SARS-CoV-2-specific T-cell immunity maintained 6 months after primary infection

Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T-cell reactivity in COVID-19-exposed donors and vaccinees

A SARS-CoV-2 reinfection rate of 1 to 1000 in members of a large health care provider in Israel: a preliminary report

previous SARS-CoV-2 infection is associated with protection against symptomatic reinfection

mRNA vaccine-induced T cells respond identically to worrisome variants of SARS-CoV-2, but differ in longevity and homing properties depending on prior infection status

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and non-COVID-19 individuals

NIH Director’s Blog: Immune T cells may offer durable protection against COVID-19

Ultrapotent antibodies against diverse and highly transmissible variants of SARS-CoV-2

Why COVID-19 vaccines should not be necessary for all Americans

Prolonged but coordinated differentiation of long-lived SARS-CoV-2-specific CD8+ CD8+ T cells during COVID-19 convalescence

Decreased measles virus-specific CD4 T cell memory in subjects

Remembrance of things past: long-term B cell memory after infection and vaccination

SARS-CoV-2-specific memory B cells from individuals with disease of varying severity recognize worrisome variants of SARS-CoV-2

Exposure to SARS-CoV-2 generates memory T cells in the absence of detectable viral infection

T cell responses in convalescent individuals with COVID-19 targeted to conserved epitopes of multiple prominent circulating variants of SARS-CoV-2

Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2

Selective and cross-reactive SARS-CoV-2 T-cell epitopes in unexposed humans observation of antibody responses for 14 months after SARS-CoV-2 infection Circulating and humoral follicular helper T cell responses in recovered patients with COVID-19

Convergent antibody responses to SARS-CoV-2 in convalescent individuals Rapid generation of durable B-cell memory for nucleocapsid proteins and SARS-CoV-2 spike in COVID-19 and convalescence Did you have COVID? You will probably produce antibodies for life Most uninfected adults show pre-existing antibody reactivity to SARS-CoV-2

T cells reactive to SARS-CoV-2 in healthy donors and patients with COVID-19

Naturally enhanced neutralizing amplitude against SARS-CoV-2 one year after infection One year after mild COVID-19: most patients maintain specific immunity, but one in four still suffer long-term symptoms IDSA–qa/07-17-21-clinician-call-slides-1.pdf

Assessment of protection against reinfection with SARS-CoV-2 among 4 million people tested for PCR in Denmark in 2020: a population-level observational study

Individual cell profiles of T- and B-cell repertoires after SARS-CoV-2 mRNA vaccination

SARS-CoV-2 antibody positivity protects against reinfection for at least seven months with 95% efficacy

SARS-CoV-2 serological assays allow surveillance of low-prevalence communities and reveal durable humoral immunity

Anti-peak antibody response to natural SARS-CoV-2 infection in general population

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

researchers find long-lasting immunity to 1918 pandemic virus

NATURE journal publication 2008

Live virus neutralization testing in convalescent patients and subjects vaccinated against SARS-CoV-2 isolates 19A, 20B, 20I / 501Y.V1 and 20H / 501Y.V2

Differential effects of the second dose of SARS-CoV-2 mRNA vaccine on T cell immunity in previously untreated and COVID-19 recovered individuals

Op-Ed: Stop ignoring natural immunity to COVID

Association of SARS-CoV-2 seropositive antibody testing with risk of future infection

SARS-CoV-2 seropositivity and risk of subsequent infection in healthy young adults: a prospective cohort study

Associations of vaccination and prior infection with positive PCR test results for SARS-CoV-2 in airline passengers arriving in Qatar

Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of serosurvey participants

Durable immunity found after recovery from COVID-19

SARS-CoV-2 natural antibody response persists for at least 12 months in a nationwide Faroese study

SARS-CoV-2-specific T-cell memory is maintained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells

Immunological memory in patients with mild COVID-19 and unexposed donors reveals persistent T-cell responses after SARS-CoV-2 infection

Natural COVID-19 immunity

Antibody evolution after vaccination with SARS-CoV-2 mRNA

Humoral immune response to SARS-CoV-2 in Iceland 

Immunological memory for SARS-CoV-2 assessed up to 8 months post infection

The prevalence of adaptive immunity to COVID-19 and reinfection after recovery: a comprehensive systematic review and meta-analysis of

Reinfection rates among patients who previously tested positive for COVID-19: a retrospective cohort study

Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy

JANUARY 8TH UPDATE: Here’s an infamous study from Denmark that shows how the vaccinated are more likely to get “covid” and how their inmune system MAY have already been compromised. God fucking damnit, can we stop pretending that the NON-vaccinated are the problem or are we that delusional???


bottom of page